FIRDAPSE® (amifampridine)
Lambert-Eaton Myasthenic Syndrome (LEMS)
Key Facts
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.
View full company profileAbout Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.
View full company profileAbout Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.
View full company profile